A Phase IB Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Hematologic Malignancies

Trial Profile

A Phase IB Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Hematologic Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Birabresib (Primary)
  • Indications Acute myeloid leukaemia; Diffuse large B cell lymphoma; Haematological malignancies
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 05 Dec 2017 Planned End Date changed from 30 Nov 2018 to 29 Dec 2017.
    • 05 Dec 2017 Planned primary completion date changed from 30 Nov 2018 to 29 Dec 2017.
    • 28 Aug 2017 Planned End Date changed from 31 Aug 2017 to 30 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top